ArticleBreast cancer research and treatment2017
Racial disparity in survival from estrogen and progesterone receptor-positive breast cancer: implications for reducing breast cancer mortality disparities.
Article in Breast cancer research and treatment, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it, 49 citations in OpenAlex.
- Racial Differences in Breast Cancer Survival Between Black and White Women According to Tumor Subtype: A Systematic Review and Meta-Analysis.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024Pooled it
- Racial disparities in outcomes of patients with stage I-III triple-negative breast cancer after adjuvant chemotherapy: a post-hoc analysis of the E5103 randomized trial.Breast cancer research and treatment · 2024Trial
- Contributions of selenoproteins to breast cancer etiology and racial disparity.Cancer causes & control : CCC · 2026Article
- Annals of Surgical Oncology Landmark Series Disparities in Surgical Oncology: Breast Cancer.Annals of surgical oncology · 2025Review
- Multiomic Analysis Links Neighborhood Disadvantage to Inflammatory Proteins and Tumorigenic Markers in ER+ Breast Cancer Plasma and Tumor Samples.Journal of proteome research · 2025Article
- A registry-based approach for estimating county-level race disparities in breast cancer mortality: an analysis in Georgia.American journal of epidemiology · 2025Article
- Dietary polyphenols and risk of breast cancer in a predominantly low-income population: a prospective analysis in the Southern Community Cohort Study (SCCS).The American journal of clinical nutrition · 2025Article
- Gene expression associated with endocrine therapy resistance in estrogen receptor-positive breast cancer.Scientific reports · 2025Article
- Epidemiology of early vs late recurrence among women with early stage estrogen receptor-positive breast cancer in the Pathways Study.Journal of the National Cancer Institute · 2024Article
- Glutamate Transport Proteins and Metabolic Enzymes are Poor Prognostic Factors in Invasive Lobular Carcinoma.bioRxiv : the preprint server for biology · 2024Article
- BIRC5 expression by race, age and clinical factors in breast cancer patients.Breast cancer research : BCR · 2024Article
- Differential response to neoadjuvant endocrine therapy for Black/African American and White women in NCDB.Breast cancer research and treatment · 2024Article
- Area Deprivation Index in Patients with Invasive Lobular Carcinoma of the Breast: Associations with Tumor Characteristics and Outcomes.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2023Article
- Identification of metabolic pathways contributing to ERScientific reports · 2023Article
- Racial and regional disparities in deaths in breast cancer.Medical oncology (Northwood, London, England) · 2023Article
- Differences in Tumour Aggressiveness Based on Molecular Subtype and Race Measured by [Diagnostics (Basel, Switzerland) · 2023Article
- Exploring the intersectionality of race/ethnicity with rurality on breast cancer outcomes: SEER analysis, 2000-2016.Breast cancer research and treatment · 2023Article
- Understanding drivers of the Black:White breast cancer mortality gap: A call for more robust definitions.Cancer · 2022Article
- Protein expression of the gp78 E3 ligase predicts poor breast cancer outcome based on race.JCI insight · 2022Article
- mTOR pathway gene expression in association with race and clinicopathological characteristics in Black and White breast cancer patients.Discover oncology · 2022Article
Corrections and comments
- Commented on by
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
introductionNon-Latina black breast cancer patients experience a shorter survival from breast cancer than their non-Latina white counterparts. We compared breast cancer-specific survival for the subset of black and white patients with estrogen and/or progesterone receptor-positive tumors that are generally targeted with endocrine therapy.
methodsUsing data collected from a population-based cohort of breast cancer patients from Chicago, IL, Kaplan-Meier survival curves and hazard functions were generated and proportional hazards models were estimated to determine the black/white disparity in time to death from breast cancer while adjusting for age at diagnosis, patient characteristics, treatment-related variables, and tumor grade and stage.
resultsIn regression models, hazard of breast cancer death among ER/PR-positive patients was at least 4 times higher for black than for white patients in all models tested. Notably, even after adjusting for stage at diagnosis, tumor grade, and treatment variables (including initiation of systemic adjuvant therapies), the hazard ratio for death from ER/PR-positive breast cancer between black and white women was 4.39 (95% CI 1.76, 10.9, p = 0.001).
conclusionsWe observed a racial disparity in breast cancer survival for patients diagnosed with ER/PR-positive tumors that did not appear to be due to differences in tumor stage, grade, or therapy initiation in black patients, suggesting that there may be racial differences in the molecular characteristics of hormone receptor-positive tumors, such that ER/PR-positive tumors in black patients may be less responsive to standard treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.